Literature DB >> 17150278

NAFLD and hyperinsulinemia are major determinants of serum ferritin levels.

Shira Zelber-Sagi1, Dorit Nitzan-Kaluski, Zamir Halpern, Ran Oren.   

Abstract

BACKGROUND/AIMS: There is an increasing body of evidence that serum ferritin is associated with the metabolic syndrome. However, no study has tested for NAFLD. The aim was to test the assumption that the association between serum ferritin and the metabolic syndrome is mediated by NAFLD.
METHODS: A cross-sectional study of a sub-sample of the first Israeli national health survey. Exclusion criteria were any known etiology for secondary NAFLD. Participants underwent an abdominal ultrasound (US), biochemical tests, and dietary and anthropometric evaluations.
RESULTS: Three hundred and forty-nine subjects were included in the analysis. Serum ferritin was higher in the NAFLD group (92.4+/-63.1 vs. 65.1+/-58.0, P<0.001). After adjusting for age and gender, the following variables were significantly associated with increased ferritin levels: abdominal obesity, hyperglycemia, hyperinsulinemia, HOMA, hypertriglyceridemia and the metabolic syndrome itself. After further adjusting for NAFLD, only abdominal obesity [2.1 (1.1-3.9)] and hyperinsulinemia [2.3 (1.3-4.2)] were still significantly associated with ferritin. In a multivariate analysis the interaction between NAFLD and hyperinsulinemia was the second strongest predictor of serum ferritin (P=0.005).
CONCLUSIONS: The association between serum ferritin and the metabolic syndrome is mediated by undiagnosed NAFLD. The interaction between NAFLD and hyperinsulinemia is a major determinant of serum ferritin levels at the population level.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17150278     DOI: 10.1016/j.jhep.2006.09.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  28 in total

1.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Kris V Kowdley; Patricia Belt; Laura A Wilson; Matthew M Yeh; Brent A Neuschwander-Tetri; Naga Chalasani; Arun J Sanyal; James E Nelson
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

Review 2.  Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver.

Authors:  Elmar Aigner; Günter Weiss; Christian Datz
Journal:  World J Hepatol       Date:  2015-02-27

3.  Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial.

Authors:  Shira Zelber-Sagi; Assaf Buch; Hanny Yeshua; Nahum Vaisman; Muriel Webb; Gil Harari; Ofer Kis; Naomi Fliss-Isakov; Elena Izkhakov; Zamir Halpern; Erwin Santo; Ran Oren; Oren Shibolet
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

5.  Non-alcoholic fatty liver disease is not associated with a lower health perception.

Authors:  Liat Mlynarsky; Dalit Schlesinger; Roni Lotan; Muriel Webb; Zamir Halpern; Erwin Santo; Oren Shibolet; Shira Zelber-Sagi
Journal:  World J Gastroenterol       Date:  2016-05-07       Impact factor: 5.742

6.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 7.  Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet.

Authors:  Ludovico Abenavoli; Natasa Milic; Valentina Peta; Francesco Alfieri; Antonino De Lorenzo; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Β-cell function in non-diabetic men and women.

Authors:  Kristina M Utzschneider; Anna Largajolli; Alessandra Bertoldo; Santica Marcovina; James E Nelson; Matthew M Yeh; Kris V Kowdley; Steven E Kahn
Journal:  J Diabetes Complications       Date:  2013-11-26       Impact factor: 2.852

Review 9.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

10.  Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?

Authors:  Giovanni Tarantino; Paolo Conca; Antonio Riccio; Marianna Tarantino; Matteo N Di Minno; Domenico Chianese; Fabrizio Pasanisi; Franco Contaldo; Francesco Scopacasa; Domenico Capone
Journal:  J Transl Med       Date:  2008-11-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.